Revenue ($USD) : $1,563,101,000
R&D spend : $60,800,000.00
Employees : 6,800
Fiscal year end : 12/31/22
CEO : Matthew Trerotola

Enovis recently upped its 2023 revenue growth projection to 7–7.5% from the prior year. CEO Matt Trerotola says the orthopedic device company is focused on innovation-driven share gain, operational improvement, and compounding impact from M&A.

Recent acquisitions include Novastep and its foot and ankle minimally invasive surgical (MIS) platform. In May, Enovis signed a definitive agreement to acquire the Seal external fixation product line from DNE. –CN